Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | MUK Nine: Tailoring treatment for patients high-risk NDMM

Matthew Jenner • 6 May 2020
Multiple Myeloma
MUK Nine b

Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, discusses data from the UKMRA OPTIMUM (MUK Nine) which looked at tailoring treatment for patients with high-risk newly diagnosed multiple myeloma. These data were submitted as an abstract to the BSH 2020 meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Jenner

Trial updates in myeloma: COLUMBA and POLLUX 4:07
Trial updates in myeloma: COLUMBA and POLLUX
Matthew Jenner • 6 May 2020
COVID-19 changing practice in Southampton 7:27
COVID-19 changing practice in Southampton
Matthew Jenner • 6 May 2020
Treatment choice for MM in UK practice 2:12
Treatment choice for MM in UK practice
Matthew Jenner • 6 May 2020
OPTIMISMM study update 2:59
OPTIMISMM study update
Matthew Jenner • 6 May 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals